Humanized antibody
First Claim
Patent Images
1. A chimeric antibody or a fragment thereof, or a humanized antibody or a fragment thereof, which specifically binds to at least one epitope on the β
- -amyloid protein wherein the epitope comprises at least two consecutive amino acid residues predominantly involved in binding to the antibody, wherein the at least two consecutive amino, acid residues are -Lys-Leu- embedded within the following core sequence (SEQ ID NO;
10);
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer'"'"'s disease.
-
Citations
152 Claims
-
1. A chimeric antibody or a fragment thereof, or a humanized antibody or a fragment thereof, which specifically binds to at least one epitope on the β
- -amyloid protein wherein the epitope comprises at least two consecutive amino acid residues predominantly involved in binding to the antibody, wherein the at least two consecutive amino, acid residues are -Lys-Leu- embedded within the following core sequence (SEQ ID NO;
10);
- View Dependent Claims (3, 4, 5, 6, 8, 12, 45, 46, 61, 70, 71, 72, 75, 81, 86, 93, 99, 100, 101, 121, 151)
- -amyloid protein wherein the epitope comprises at least two consecutive amino acid residues predominantly involved in binding to the antibody, wherein the at least two consecutive amino, acid residues are -Lys-Leu- embedded within the following core sequence (SEQ ID NO;
-
2. (canceled)
-
7. (canceled)
-
9. (canceled)
-
10. (canceled)
-
11. (canceled)
-
13. (canceled)
-
14. (canceled)
-
15. (canceled)
-
16. (canceled)
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
-
21. (canceled)
-
22. (canceled)
-
23. (canceled)
-
24. (canceled)
-
25. (canceled)
-
26. (canceled)
-
27. (canceled)
-
28. (canceled)
-
29. (canceled)
-
30. (canceled)
-
31. (canceled)
-
32. (canceled)
-
33. (canceled)
-
34. (canceled)
-
35. (canceled)
-
36. (canceled)
-
37. (canceled)
-
38. (canceled)
-
39. (canceled)
-
40. (canceled)
-
41. (canceled)
-
42. (canceled)
-
43. (canceled)
-
44. (canceled)
-
47. (canceled)
-
48. (canceled)
-
49. (canceled)
-
50. (canceled)
-
51. (canceled)
-
52. (canceled)
-
53. (canceled)
-
54. (canceled)
-
55. (canceled)
-
56. (canceled)
-
57. (canceled)
-
58. (canceled)
-
59. (canceled)
-
60. (canceled)
-
62. A nucleic acid molecule comprising a nucleotide sequence encoding a humanized light chain variable region comprising SEQ ID NO:
- 12.
-
63. A nucleic acid molecule comprising a nucleotide sequence encoding a humanized heavy chain variable region comprising SEQ ID NO:
- 15.
-
64. (canceled)
-
65. (canceled)
-
66. (canceled)
-
67. (canceled)
-
68. (canceled)
-
69. (canceled)
-
73. (canceled)
-
74. (canceled)
-
76. (canceled)
-
77. (canceled)
-
78. (canceled)
-
79. (canceled)
-
80. (canceled)
-
82. (canceled)
-
83. (canceled)
-
84. (canceled)
-
85. (canceled)
-
87. (canceled)
-
88. (canceled)
-
89. (canceled)
-
90. (canceled)
-
91. (canceled)
-
92. (canceled)
-
94. (canceled)
-
95. (canceled)
-
96. (canceled)
-
97. (canceled)
-
98. (canceled)
-
102. (canceled)
-
103. (canceled)
-
104. (canceled)
-
105. Heavy Chain Variable Region (HCVR) comprising human- or primate-derived heavy chain framework regions and at least two CDRs with an amino acid sequence selected from the group of sequences consisting of SEQ ID NO:
- 1 representing CDR1, SEQ ID NO;
2 representing CDR2 and SEQ ID NO;
3 representing CDR3 of the Heavy Chain Variable Region (HCVR).
- 1 representing CDR1, SEQ ID NO;
-
106. Light Chain Variable Region (LCVR),comprising human- or primate-derived light chain framework regions and at least two CDRs with an amino acid sequence selected from the group of sequences consisting of SEQ ID NO:
- 4 representing CDR1, SEQ ID NO;
5 representing CDR2 and SEQ ID NO;
6 representing CDR3 of the Light Chain Variable Region (LCVR).
- 4 representing CDR1, SEQ ID NO;
-
107. (canceled)
-
108. (canceled)
-
109. (canceled)
-
110. (canceled)
-
111. (canceled)
-
112. (canceled)
-
113. A humanized antibody or a fragment thereof, which comprises the Light Chain Variable Region (LCVR) of SEQ ID NO:
- 12 and the light chain constant region of SEQ ID NO;
14.
- 12 and the light chain constant region of SEQ ID NO;
-
114. (canceled)
-
115. (canceled)
-
116. (canceled)
-
117. (canceled)
-
118. (canceled)
-
119. A humanized antibody or a fragment thereof, which comprises the Heavy Chain Variable Region (HCVR) of SEQ ID NO:
- 15 and the heavy chain constant region of SEQ ID NO;
17.
- 15 and the heavy chain constant region of SEQ ID NO;
-
120. A humanized antibody or a fragment thereof, which comprises the Heavy Chain of SEQ ID NO:
- 16.
-
122. (canceled)
-
123. (canceled)
-
124. (canceled)
-
125. (canceled)
-
126. (canceled)
-
127. (canceled)
-
128. (canceled)
-
129. (canceled)
-
130. (canceled)
-
131. (canceled)
-
132. (canceled)
-
133. (canceled)
-
134. (canceled)
-
135. (canceled)
-
136. (canceled)
-
137. (canceled)
-
138. (canceled)
-
139. (canceled)
-
140. (canceled)
-
141. (canceled)
-
142. (canceled)
-
143. (canceled)
-
144. (canceled)
-
145. (canceled)
-
146. (canceled)
-
147. (canceled)
-
148. (canceled)
-
149. A method for disaggregating preformed beta-amyloid fibers, comprising interacting an hC2 antibody with preformed beta-amyloid fibers.
-
150. (canceled)
-
152. (canceled)
Specification